ArticleToxics2024
Artificial Intelligence and Machine Learning Methods to Evaluate Cardiotoxicity following the Adverse Outcome Pathway Frameworks.
Article in Toxics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Review on Predictive Models and Integration Strategies for Holistic Impact Assessment of Chemicals and Materials.Environmental science & technology · 2026Review
- Mapping the Rise in Machine Learning in Environmental Chemical Research: A Bibliometric Analysis.Toxics · 2025Review
- Mixture of experts for multitask learning in cardiotoxicity assessment.Journal of cheminformatics · 2025Article
- Machine Learning-Enabled Drug-Induced Toxicity Prediction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Advancing human health risk assessment: the role of new approach methodologies.Frontiers in toxicology · 2025Review
- Quantitative structure-activity relationships of chemical bioactivity toward proteins associated with molecular initiating events of organ-specific toxicity.Journal of cheminformatics · 2024Article
- Machine learning and molecular docking prediction of potential inhibitors against dengue virus.Frontiers in chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiovascular disease is a leading global cause of mortality. The potential cardiotoxic effects of chemicals from different classes, such as environmental contaminants, pesticides, and drugs can significantly contribute to effects on health. The same chemical can induce cardiotoxicity in different ways, following various Adverse Outcome Pathways (AOPs). In addition, the potential synergistic effects between chemicals further complicate the issue. In silico methods have become essential for tackling the problem from different perspectives, reducing the need for traditional in vivo testing, and saving valuable resources in terms of time and money. Artificial intelligence (AI) and machine learning (ML) are among today's advanced approaches for evaluating chemical hazards. They can serve, for instance, as a first-tier component of Integrated Approaches to Testing and Assessment (IATA). This study employed ML and AI to assess interactions between chemicals and specific biological targets within the AOP networks for cardiotoxicity, starting with molecular initiating events (MIEs) and progressing through key events (KEs). We explored methods to encode chemical information in a suitable way for ML and AI. We started with commonly used approaches in Quantitative Structure-Activity Relationship (QSAR) methods, such as molecular descriptors and different types of fingerprint. We then increased the complexity of encoders, incorporating graph-based methods, auto-encoders, and character embeddings employed in neural language processing. We also developed a multimodal neural network architecture, capable of considering the complementary nature of different chemical representations simultaneously. The potential of this approach, compared to more conventional architectures designed to handle a single encoder, becomes apparent when the amount of data increases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.